MedTrace Logo

ERA Test in Patients With Recurrent Implantation Failure

NCT01668693 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2015-10-19

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the clinical efficiency of the Endometrial Receptivity Array (ERA) diagnostic tool in patients with repetitive implantation failure (RIF), leading to the new concept of the personalized window of implantation (pWOI) as diagnostic and treatment of patients with RIF of endometrial origin.

Conditions

  • Repetitive Implantation Failure

Interventions

OTHER

ERA (Endometrial Receptivity Array)

The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group "Receptive" or "Non Receptive" and to predict the number of days of Progesterone administration necesary to obtain the "Receptive" prediction.

OTHER

Personalized Embryo Transfer

When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.

OTHER

Second ERA

A second ERA will be performed to confirm receptivity after further administration of Progesterone.

Sponsors & Collaborators

  • Igenomix

    lead INDUSTRY

Principal Investigators

  • Carlos Simón, MD PhD · ºIGENOMIX / IVI Valencia

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2016-04-30
Completion
2016-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01668693 on ClinicalTrials.gov